Educational seminar: "Diagnosis of homologous recombination (HR-) deficiency..."

Welcome to the CONNECT Educational Seminar:

«Diagnosis of homologous recombination (HR-) deficiency. Existing & emerging technologies - how to compare?»

Host: CONNECT Working Group 1 interfacing InPreD

Date: Monday, June 7th, 2021, 15:00 – 17:00h CEST

Venue: Digital Meeting via Zoom or TEAMS. Please note: the meeting will be recorded.

MEETING LINK & how to attend details TBC

AGENDA

15:00h – 15:05h Welcome

Hilde Nilsen, Head of The Department of Clinical Molecular Biology at Akershus University Hospital (member of TSC in IMPRESS, member of InPreD)

15:05h - 16:05h «Homologous Recombination Deficiency: Targeting the DNA damage response in cancer»

Simon J. Boulton, Senior Group Leader, The Francis Crick Institute, honorary Professor at University College London and VP Science Strategy at Artios Pharma

45 min presentation followed by 15 min Q&A

16:00h – 16:35h «The Nordic HRD LDT Consortium – experience and outlook from Denmark and Finland»

Introduction by Per B. Andersen, Nordic Diagnostic Manager, AstraZeneca Nordic

Maria Rossing,

5 min introduction, 20 min presentation followed by 10 min Q&A

16:30h – 17:00h Discussion

Contact: Jutta Heix, Head of International Affairs Oslo Cancer Cluster / Project Lead CONNECT; jh@oslocancercluster.no

Simon J Boulton is a Senior Group Leader and Ambassador for Translation at the Francis Crick Institute in London (https://www.crick.ac.uk/research/find-a-researcher/simon-boulton). His lab has discovered novel DNA repair genes and provided molecular insights into their impact on human diseases. His important contributions to understanding mechanisms of DNA repair, including homologous recombination, and how these can be exploited to treat cancer has been acknowledge by a number of prestigious accolades, notably the EMBO Gold Medal and the Paul Marks Prize for Cancer Research. He has also given numerous prize lectures, most notably the Royal Society Francis Crick Prize lecture and the Mendel Lecture.

Simon J Boulton is also a VP Science Strategy at Artios Pharma, where he plays an important role in assisting the business development team in the identification and evaluation of new pipeline opportunities from the global academic and industrial DDR network (https://www.artiospharma.com/)